An international life sciences company has leased 40,000 square feet of office space in White Marsh to expand its local manufacturing of a brain cancer drug.
Eisai Inc. signed a lease with St. John Properties to move 55 employees from Baltimore City to Baltimore County by 2019.
The office is located at 11675 Crossroads Cir. in newly constructed office space at Greenleigh at Crossroads, located off of Route 43. The company currently has offices and manufacturing space in Southeast Baltimore near the Amazon.com distribution center on Broening Highway.
Tokyo-based Eisai Co. Ltd, the parent company of Eisai Inc., studies and manufactures pharmaceuticals for oncology and neurology patients.
In the new White Marsh offices, the company will manufacture and distribute a brain cancer drug, Gliadel, a treatment that is implanted in the brain as a biodegradable wafer.
"This new Baltimore location enables Eisai a seamless transition in its efforts to continue to produce Gliadel for thousands of patients worldwide," said Shaji Procida, president of Eisai Inc., in a statement. "It also demonstrates our commitment to constantly improve our services in areas of unmet need and to remain nimble to adapt to our changing business environment."
Richard Williamson, senior vice president at St. John, said in a statement that the lease signifies an "influx of high-paying jobs" at Greenleigh that broke ground last year and is expected to attract 10,000 new jobs when it is built out.
The $750 million project will encompass 1,000 acres just off of Interstate 95 with more than 2.5 million square feet of commercial, office, flex-and research and development space, as well as warehouse, industrial and retail. There is also a residential component.
"Attracting strong economic generators to Baltimore County was an extremely high priority in the design and planning of the community," Williamson said.
Eisai has a U.S. headquarters in Woodcliff Lake, New Jersey, and has labs in Massachusetts and Pennsylvania.
Baltimore Business Journal